Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Tumor-Agnostic 2Lymphoid 2Sarcoma 1Plasma cell 1Genitourinary 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Immunoconjugates × Tumor-Agnostic × Clear all
NCT07052760 2026-04-29

Imaging of Solid Tumors Using DLL3 SPECT

University of California, San Francisco

Phase EARLY_PHASE1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

MBrace Therapeutics

Phase 1/2 Recruiting
130 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡